멀티플렉스 어세이 시장 : 예측(2026-2031년)

The multiplex assay market is forecasted to increase at a 15.45% CAGR, growing from USD 1,607.267 million in 2025 to USD 3806.265 million in 2031.

The multiplex assay market is experiencing significant growth driven by technological advancement, evolving healthcare paradigms, and increasing analytical complexity demands. These sophisticated scientific techniques, enabling simultaneous measurement of multiple analytes or targets within a single sample, have become indispensable tools across biochemistry, molecular biology, medicine, and diagnostics. The convergence of biotechnology sector expansion, personalized medicine adoption, and rising chronic disease prevalence is propelling market momentum.

Core Market Drivers

Intrinsic Technological Advantages

Multiplex assays offer compelling benefits compared to traditional singleplex tests, making them highly valuable across research, diagnostic, and clinical applications. The most significant advantage lies in their ability to analyze multiple analytes-including proteins, nucleic acids, or other molecules-simultaneously within a single sample. This capability provides comprehensive, holistic views of biological processes, disease pathways, and drug responses that would be impossible or impractical to achieve through sequential singleplex testing.

Furthermore, multiplex assays enhance diagnostic accuracy by considering multiple biomarkers or disease indicators concurrently. This multi-parameter approach reduces the likelihood of false positives or negatives, yielding more reliable results and improved patient outcomes. The efficiency gains from analyzing numerous targets simultaneously translate to reduced sample volumes, decreased reagent consumption, faster turnaround times, and lower overall costs per data point-critical considerations in both research and clinical settings.

Pharmaceutical and Biotechnology Expansion

The expanding pharmaceutical sector and advances in molecular diagnostics are substantial market catalysts. Continuous progress in biotechnology, genomics, and proteomics has enabled identification of numerous potential biomarkers and therapeutic targets. Multiplex assays play crucial roles in assessing potential drug effects on multiple targets simultaneously, accelerating drug development timelines and improving research efficiency. The biotechnology landscape is expanding rapidly, with India's biotech startup ecosystem expected to reach 10,000 companies by 2025, demonstrating the sector's global growth trajectory and associated demand for sophisticated analytical tools like multiplex assays.

Personalized Medicine Integration

The healthcare industry's shift toward personalized medicine requires comprehensive understanding of multiple biomarkers, positioning multiplex assays as essential enabling technologies. These assays facilitate simultaneous analysis of diverse genetic, proteomic, and molecular markers, supporting development of tailored treatment strategies optimized for individual patient profiles. The growing adoption of personalized medicine is evidenced by emerging business models-exemplified by the May 2023 launch of Malla, a New York-based startup offering functional and personalized medicine through accessible membership models at $65 monthly, including one-to-one consultations for personalized health planning.

Chronic Disease and Demographic Pressures

Multiplex assays have proven invaluable in studying and managing chronic diseases, offering capabilities to track biomarker changes over time and providing insights into disease dynamics. The rising chronic disease prevalence represents a significant growth driver, with these conditions accounting for 41 million deaths annually-74% of all deaths worldwide. The analytical power of multiplex assays enables comprehensive disease monitoring and management strategies that would be impractical using conventional methods.

Additionally, the growing geriatric population accelerates multiplex assay demand, as elderly individuals commonly present with multiple concurrent conditions including cardiovascular disease and diabetes, requiring complex diagnostic approaches. The demographic shift is substantial: the proportion of people aged over 60 years worldwide is projected to increase from 12% to 22% between 2015 and 2050, creating sustained demand for efficient multi-parameter diagnostic solutions.

Market Constraints

Despite robust growth prospects, the multiplex assay market faces challenges that may impact expansion. Cost represents a significant limiting factor, with initial setup expenses and ongoing costs associated with multiplex assays remaining relatively high. This includes equipment acquisition, reagents, and specialized expertise requirements for assay design and data analysis. These financial barriers may limit adoption, particularly in resource-constrained settings where budget limitations preclude investment in advanced analytical platforms.

Additionally, designing and optimizing multiplex assays involves greater complexity than traditional singleplex approaches. Development requires careful consideration of factors including cross-reactivity, sensitivity, and dynamic range for each analyte, making the process time-consuming and resource-intensive.

Regional Dynamics and Recent Developments

North America is positioned to hold significant market share during the forecast period, supported by higher chronic disease prevalence, growing geriatric populations, increasing R&D spending on drug development, and government support. Approximately one in six people in the U.S. were aged 65 years or above in 2020, accelerating multiplex assay demand.

Recent market developments underscore ongoing innovation. In February 2023, Quansys Biosciences launched a non-human primate model line of multiplex ELISA assays comprising four customizable kits. The multiplex assay market continues evolving, driven by technological sophistication, healthcare transformation, and analytical demands of modern medicine and research.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Multiplex Assay Market Segmentation

• By Type
• Protein Multiplex Assays
• Nucleic Acid Multiplex Assays
• Cell-based Multiples Assays
• By Product
• Consumables
• Instruments
• Software
• By Technology
• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-time PCR
• Other Technologies
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLEX ASSAY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Protein Multiplex Assays
• 5.3. Nucleic Acid Multiplex Assays
• 5.4. Cell-based Multiples Assays

6. MULTIPLEX ASSAY MARKET BY PRODUCT

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Instruments
• 6.4. Software

7. MULTIPLEX ASSAY MARKET BY TECHNOLOGY

• 7.1. Introduction
• 7.2. Flow Cytometry
• 7.3. Fluorescence Detection
• 7.4. Luminescence
• 7.5. Multiplex Real-time PCR
• 7.6. Other Technologies

8. MULTIPLEX ASSAY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Luminex
• 10.2. Promega
• 10.3. Rndsystems (Biotechne Corporation)
• 10.4. Eve Technologies
• 10.5. Sigma-Aldrich
• 10.6. Bio-Techne
• 10.7. Merck Millipore
• 10.8. Biocompare
• 10.9. Flagship Biosciences

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations